沙库巴曲缬沙坦在高血压中的应用

摘要
图/表
参考文献(34)
相关文章 (15)

全文: PDF (0 KB) HTML (40 KB)
输出: BibTeX | EndNote (RIS)

摘要高血压是我国最常见的心血管疾病，目前我国高血压的控制率极低，长期控制不佳的高血压会出现心脑肾等靶器官的严重并发症。近几年来肾素-血管紧张素-醛固酮系统（RAAS）和利钠肽（NP）系统的激活越发引起人们重视。沙库巴曲缬沙坦作为目前唯一一种血管紧张素脑啡肽酶抑制剂，能够同时作用于RAAS 系统及NP 系统，可作为高血压患者的新选择。本文通过复习沙库巴曲缬沙坦用于高血压治疗的临床研究，总结及综述了沙库巴曲缬沙坦在高血压治疗中的优势。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	王君
	张静
	宫航宇

关键词 ：沙库巴曲缬沙坦, 单纯收缩期高血压, 盐敏感性高血压, 慢性肾病, 肥胖, 心力衰竭

Abstract：Hypertension is the most common cardiovascular disease in China.At present,the control rate of hypertension in China is very low.Long-term poorly controlled hypertension will cause serious complications in target organs such as heart,brain and kidney.In recent years,the activation of renin-angiotensin-aldosterone system (RAAS)and natriuretic peptide(NP)system has attracted increasing attention.As the only angiotensin-enkephalase inhibitor,Sacubitril/Valsartan can act on both the RAAS system and the NP system,and can be used as a new choice for patients with hypertension.In this paper,the advantages of Sacubitril/Valsartan in the treatment of hypertension were summarized by reviewing the clinical studies of Sacubitril/Valsartan in the treatment of hypertension.

Key words： Sacubitril/Valsartan Isolated systolic hypertension Salt sensitive hypertension Chronic kindney disease Obesity Heart failure

基金资助:辽宁省大连市医学科学研究计划项目（1911039）

引用本文:

王君；张静；宫航宇. 沙库巴曲缬沙坦在高血压中的应用[J]. 中国当代医药, 2021, 28(6): 26-29转34.
WANG Jun；ZHANG Jing；GONG Hang-yu. Application of Sacubitril/Valsartan in hypertension. 中国当代医药, 2021, 28(6): 26-29转34.

链接本文:

http://dangdaiyiyao.com/CN/ 或 http://dangdaiyiyao.com/CN/Y2021/V28/I6/26

[2]	Singh JSS，Burrell LM，Cherif M，et al.Sacubitril/Valsartan：beyond natriuretic peptides[J].Heart，2017，103（20）：1569-1577.
[7]	Malik AH，Aronow WS.Efficacy of Sacubitril/Valsartan in Hypertension[J].Am J Ther，2019，10.[Epub ahead of print].
[10]	《中国高血压防治指南》修订委员会.中国高血压防治指南2018年修订版[J].中国心血管病杂志，2019，24（1）：24-56.
[16]	Sanada H，Jones JE，Jose PA.Genetics of salt-sensitive hypertension[J].Curr Hypertens Rep，2011，13（1）：55-66.
[1]	Wang Z，Chen Z，Zhang L，et al.Status of Hypertension in China：Results From the China Hypertension Survey，2012-2015[J].Circulation，2018，137（22）：2344-2356.
[3]	Vaduganathan M，McMurray JJV，Solomon SD.Angiotensin Receptor-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction：Lessons from PARAGON-HF[J].Eur J Heart Fail，2020，22（9）：1525-1530.
[4]	Okumura N，Jhund PS，Gong J，et al.Importance of Clinical Worsening of Heart Failure Treated in the Outpatient Setting：Evidence From the Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial （PARADIGM-HF）[J].Circulation，2016，133（23）：2254-2262.
[5]	Kjeldsen SE，Hedner T，Narkiewicz K，et al.Angiotensin receptor neprilysin inhibition （ARNI） a novel therapeutic concept for management of hypertension and heart failure[J].Blood Press，2012，21（6）：329-330.
[6]	Lu J，Lu Y，Wang X，et al.Prevalence，awareness，treatment，and control of hypertension in China：data from 1.7 million adults in a population-based screening study （China PEACE Million Persons Project）[J].Lancet，2017，390（10 112）：2549-2558.
[8]	Kario K.The Sacubitril/Valsartan，a First-in-Class，Angiotensin Receptor Neprilysin Inhibitor （ARNI）：Potential Uses in Hypertension，Heart Failure，and Beyond[J].Curr Cardiol Rep，2018，20（1）：5.
[9]	Huo Y，Li W，Webb R，et al.Efficacy and safety of Sacubitril/Valsartan compared with olmesartan in Asian patients with essential hypertension：A randomized，double-blind，8-week study[J].J Clin Hypertens （Greenwich），2019，21（1）：67-76.
[11]	Franklin SS，Jacobs MJ，Wong ND，et al.Predominance of isolated systolic hypertension among middle aged and elderly US hypertensives：analysis based on National Health and Nutrition Examination Survey （NHANES）Ⅲ[J].Hypertension，2001，37（3）：869-874.
[12]	Kim NR，Kim HC.Prevalence and Trends of Isolated Systolic Hypertension among Korean Adults：the Korea National Health and Nutrition Examination Survey，1998-2012[J].Korean Circ J，2015，45（6）：492-499.
[13]	Wang JG，Yukisada K，Sibulo A，et al.Efficacy and safety of Sacubitril/Valsartan （LCZ696） add-on to Amlodipine in Asian patients with systolic hypertension uncontrolled with Amlodipine monotherapy[J].J Hypertens，2017，35（4）：877-885.
[14]	Supasyndh O，Wang J，Hafeez K，et al.Efficacy and Safety of Sacubitril/Valsartan (LCZ696) Compared With Olmesartan in Elderly Asian Patients(≥65 Years)With Systolic Hypertension[J].Am J Hypertens，2017，30（12）：1163-1169.
[15]	Williams B，Cockcroft JR，Kario K，et al.Effects of Sacubitril/Valsartan Versus Olmesartan on Central Hemodynamics in the Elderly With Systolic Hypertension：The PARAMETER Study[J].Hypertension，2017，69（3）：411-420.
[17]	Kario K，Sun N，Chiang FT，et al.Efficacy and safety of LCZ696，a first-in-class angiotensin receptor neprilysin inhibitor，in Asian patients with hypertension：a randomized，double-blind，placebo-controlled study[J].Hypertension，2014，63（4）：698-705.
[18]	Wang TD，Tan RS，Lee HY，et al.Effects of sacubitril/valsartan （LCZ696） on natriuresis，diuresis，blood pressures，and NT-proBNP in saltsensitive hypertension[J].Hypertension，2017，69（1）：32-41.
[19]	中华医学会心血管病学分会心力衰竭学组，中国医师协会心力衰竭专业委员会，中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2018[J].中华心力衰竭和心肌病杂志（中英文），2018，2（4）：196-225.
[20]	Solomon SD，Zile M，Pieske B，et al.The angiotensin receptor eprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction：a phase 2 double blind randomised controlled trial[J].Lancet，2012，380（9851）：1387-1395.
[21]	Jhund PS，Claggett B，Packer M，et al.Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor，LCZ696，in patients with heart failure with preserved ejection fraction：an analysis of the PARAMOUNT trial[J].Eur J Heart Fail，2014，16（6）：671-677.
[22]	Solomon SD，McMurray JJV，Anand IS，et al.Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction[J].N Engl J Med，2019，381（17）：1609-1620.
[23]	Zhang W，Shi W，Liu Z，et al.A nationwide cross-sectional survey on prevalence，management and pharmacoepidemiology patterns on hypertension in Chinese patients with chronic kidney disease[J].Sci Rep，2016，6（38 768）：1-10.
[24]	Zheng Y，Cai GY，Chen XM，et al.Prevalence，awareness，treatment，and control of hypertension in the non-dialysis chronic kidney disease patients[J].Chin Med J （Engl），2013，126（12）：2276-2280.
[25]	林静，丁吉俊，傅辰生，等.慢性肾脏病患者高血压现状的横断面调查[J].中华肾脏病杂志，2009，11（25）：827-831.
[26]	Ito S，Satoh M，Tamaki Y，et al.Safety and efficacy of LCZ696，a first-in-class angiotensin receptor neprilysin inhibitor，in Japanese patients with hypertension and renal dysfunction[J].Hypertens Res，2015，38（4）：269-275.
[27]	Voors AA，Gori M，Liu LC，et al.Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction[J].Eur J Heart Fail，2015，17（5）：510-517.
[28]	UK HARP-ⅢCollaborative Group.Randomized multicentre pilot study of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease：United Kingdom Heart and Renal Protection（HARP）-Ⅲ-rationale，trial design and baseline data[J].Nephrol Dial Transplant，2017，32（12）：2043-2051.
[29]	Standeven KF，Hess K，Carter AM，et al.Neprilysin，obesity and the metabolic syndrome[J].Int J Obes （Lond），2011，35（8）：1031-1040.
[30]	Jordan J，Stinkens R，Jax T，et al.Improved Insulin Sensitivity With Angiotensin Receptor Neprilysin Inhibition in Individuals With Obesity and Hypertension[J].Clin Pharmacol Ther，2017，101（2）：254-263.
[31]	Engeli S，Stinkens R，Heise T，et al.Effect of Sacubitril/Valsartan on Exercise-Induced Lipid Metabolism in Patients With Obesity and Hypertension[J].Hypertension，2018，71（1）：70-77.
[32]	Stinkens R，van der Kolk BW，Jordan J，et al.The effects of angiotensin receptor neprilysin inhibition by Sacubitril/Valsartan on adipose tissue transcriptome and protein expression in obese hypertensive patients[J].Sci Rep，2018，8（1）：1-7.
[33]	Nielsen PM，Grimm D，Wehland M，et al.The Combination of Valsartan and Sacubitril in the Treatment of Hypertension and Heart Failure-an Update[J].Basic Clin Pharmacol Toxicol，2018，122（1）：9-18.
[34]	Shi V，Senni M，Streefkerk H，et al.Angioedema in heart failure patients treated with Sacubitril/Valsartan （LCZ696）or enalapril in the PARADIGM-HF study[J].Int J Cardiol，2018，264：118-123.